← Back to Search

Monoclonal Antibodies

Aflibercept for Neovascular Glaucoma

N/A
Waitlist Available
Led By Malik Y Kahook, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 year
Awards & highlights

Summary

This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation. The investigators hypothesize that the neovascularization of the iris and angle present in neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept injection alone and result in increased comfort and preservation of visual field as compared to current standard of care utilizing pan-retinal photocoagulation. The advantages to intravitreal aflibercept injection use could include resolution of NVI/NVA (neovascularization of the iris/neovascularization of the angle) leading to quicker pain relief and quicker lowering of IOP (intraocular pressure).

Eligible Conditions
  • Neovascular Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Adverse Events
Severity of Adverse Events
Secondary outcome measures
Comparison of the Visual Field Between Groups
Evaluation of the Average Retinal Nerve Fiber Layer (RNFL)
Extent of Resolution of Neovascularization Between Groups
+10 more

Side effects data

From 2015 Phase 4 trial • 26 Patients • NCT01617148
4%
Cataract progression
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Group

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AfliberceptExperimental Treatment1 Intervention
2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
Group II: Aflibercept with LaserActive Control1 Intervention
A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aflibercept
2016
Completed Phase 4
~2540

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,786 Previous Clinical Trials
2,787,601 Total Patients Enrolled
Malik Y Kahook, MDPrincipal InvestigatorUniversity of Colorado, Denver
1 Previous Clinical Trials
60 Total Patients Enrolled
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top